Genmab — April 2013
-
Jeg tror data er for tynde, først realistisk når de har fase 2 data.
-
Arzerra royalty???
-
Mit bud: 31miokr
-
25 mill
-
undskyld 35 mill

-
125/4 = 31 (som er guidiance). Men Jan har jo sagt at de 125 var konservativ guidiance
-
jeg tror ikke på off label salg under nogen omstændigheder, med mindre data er insane
-
Jeg tror på off-label salg i CLL 2nd line og vedligehold, hvis ellers Frontline data er gode.
-
Hvis godkendt i 1st line og 3rd line kan det bruges på hele paletten.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind